Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC

Ruth Aiwu He, MD, PhD, scientific lead in liver and biliary cancers at Georgetown-Lombardi Comprehensive Cancer Center, discusses the results of the LEGACY study in patients with hepatocellular carcinoma (HCC).

The LEGACY study was a retrospective analysis of patients with early-stage HCC who received Y-90 glass microspheres (TheraSphere), according to He. In the overall cohort, Y-90 demonstrated a best overall response rate of 88%, with a complete response rate of 83%, says He.

Additionally, the therapy resulted in prolonged disease control, and the 3-year overall survival rate in patients with transplant or resection following Y-90 was 93%, says He. Overall, the results of the study appear to be quite promising, He concludes.